|1.||Wang, Wei: 7 articles (03/2008 - 04/2006)|
|2.||Yu, Zhi-yuan: 4 articles (08/2007 - 04/2006)|
|3.||Tian, Dai-shi: 4 articles (08/2007 - 04/2006)|
|4.||Xie, Min-jie: 4 articles (08/2007 - 04/2006)|
|5.||Strnad, M: 3 articles (01/2004 - 11/2000)|
|6.||Yu, Zhi-Yuan: 2 articles (03/2008 - 10/2006)|
|7.||Bu, Bi-Tao: 2 articles (03/2008 - 10/2006)|
|8.||Zhang, Liang: 2 articles (03/2008 - 04/2007)|
|9.||Witte, Otto W: 2 articles (03/2008 - 10/2006)|
|10.||Xie, Min-Jie: 2 articles (03/2008 - 10/2006)|
10/01/2012 - "Restoration of TFF1 expression in AGS cells suppressed tumor cell viability and arrested AGS cells in the G1-S transition phase after olomoucine treatment. "
08/01/2009 - "Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?"
05/01/2003 - "The compounds 32a,b exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine."
11/01/2000 - "These results indicate that the cellular effects of olomoucine-derived CDKIs are not dependent on their ability to inhibit CDKs and could be mediated by several factors such as a decrease in protein synthesis and/or glycolysis which in turn diminishes the ability of cancer cells to function."
07/01/1999 - "Compound 21 proved cytotoxic against human tumor HeLa cells (LD50-6.7 microM versus 42.7 microM for olomoucine, 24-h contact). "
|2.||Wounds and Injuries (Trauma)
03/02/2007 - "In the olomoucine-treated group, a significant reduction of activated and/or proliferated microglial induced IL-1beta expression was observed 24 h after SCI. Moreover, olomoucine evidently attenuated the number of apoptotic neurons after SCI. Our findings suggest that modulation of microglial proliferation with associated proinflammatory cytokine expression may be a mechanism of cell cycle inhibition-mediated neuroprotections in the CNS trauma."
01/01/2008 - "The increased localization of MMP-9 within epithelial cells at the wound edge was further enhanced by olomoucine while the expression of MMP-2 was reduced. "
08/15/2004 - "Inhibiting Cdk5 activity with olomoucine or a dominant negative construct, Cdk5T33, increased the concentration of Src(pY416), shifted its subcellular localization to the cell periphery and enhanced wound closure. "
01/01/2008 - "The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo."
08/15/2004 - "Conversely, the Cdk5 inhibitor, olomoucine, accelerated debridement wound healing in organ cultured eyes of normal mice, caused migrating cells to separate from the epithelial cell sheet, and increased the level of activated Src(pY416) along the wound edge. "
11/01/1999 - "Cellular effects of olomoucine in human lymphoma cells differing in p53 function."
11/01/1999 - "Therefore, our results give an impetus to continued research into olomoucine that might be a very useful chemotherapeutic strategy in the treatment of patients with mutant p53 tumors, at least in lymphoma patients."
|4.||Prostatic Neoplasms (Prostate Cancer)
08/01/2002 - "The aim of this study was to analyse alterations of the regulatory pathways in both androgen sensitive and androgen insensitive prostatic cancer cell lines (LNCaP and DU-145, respectively) after blockage of the cell cycle by the synthetic CDK inhibitors, olomoucine and bohemine. "
01/01/2004 - "Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines."
01/01/2004 - "The present study focuses on the effect of the combined synthetic cyclin-dependent kinase [CDK] inhibitor, olomoucine and the antiandrogen bicalutamide on hormone-insensitive (DU-145) and hormone-sensitive (LNCaP) prostate cancer cell lines. "
02/01/2011 - "We evaluated the effects of aloisine A, alsterpaullone, aminopurvalanol, indirubin-3'-oxime, 6-Br-indirubin-3'-oxime, kenpaullone, olomoucine and roscovitine on cell proliferation, prostate-specific antigen (PSA) expression, androgen receptor (AR) activation, and GSK-3β and β-catenin expression in androgen-dependent LNCaP human prostate cancer cells. "
|5.||Spinal Cord Injuries (Spinal Cord Injury)
03/02/2007 - "In the present study, we sought to determine the influence of olomoucine on microglial proliferation with associated inflammatory response after spinal cord injury. "
10/15/2014 - "To determine whether olomoucine acts synergistically with bone morphogenetic protein-4 in the treatment of spinal cord injury, we established a rat model of acute spinal cord contusion by impacting the spinal cord at the T8 vertebra. "
10/15/2014 - "Synergistic actions of olomoucine and bone morphogenetic protein-4 in axonal repair after acute spinal cord contusion."
06/18/2007 - "Attenuation of astrogliosis by suppressing of microglial proliferation with the cell cycle inhibitor olomoucine in rat spinal cord injury model."
03/02/2007 - "Suppression of astroglial scar formation and enhanced axonal regeneration associated with functional recovery in a spinal cord injury rat model by the cell cycle inhibitor olomoucine. "